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Objectives The purpose of this study was to determine whether coenzyme Q10 is an independent predictor of prognosis in heart failure.
Background Blood and tissue concentrations of the essential cofactor coenzyme Q10 are decreased by statins, and this could
be harmful in patients with heart failure.
Methods We measured serum coenzyme Q10 in 1,191 patients with ischemic systolic heart failure enrolled in CORONA
(Controlled Rosuvastatin Multinational Study in Heart Failure) and related this to clinical outcomes.
Results Patients with lower coenzyme Q10 concentrations were older and had more advanced heart failure. Mortality
was significantly higher among patients in the lowest compared to the highest coenzyme Q10 tertile in a univari-
ate analysis (hazard ratio: 1.50, 95% confidence interval: 1.04 to 2.6, p  0.03) but not in a multivariable analy-
sis. Coenzyme Q10 was not an independent predictor of any other clinical outcome. Rosuvastatin reduced coen-
zyme Q10 but there was no interaction between coenzyme Q10 and the effect of rosuvastatin.
Conclusions Coenzyme Q10 is not an independent prognostic variable in heart failure. Rosuvastatin reduced coenzyme Q10, but
even in patients with a low baseline coenzyme Q10, rosuvastatin treatment was not associated with a significantly
worse outcome. (Controlled Rosuvastatin Multinational Study in Heart Failure [CORONA]; NCT00206310)
(J Am Coll Cardiol 2010;56:1196–204) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.02.075l
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Moenzyme Q10 (ubiquinone) is a naturally occurring, lipid-
oluble, quinone which, by acting as an electron transporter,
s an essential cofactor in mitochondrial oxidative phosphor-
lation and generation of adenosine triphosphate (1,2). In
ts reduced form, coenzyme Q10 is also thought to act as a
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oproteins in the circulation from oxidation (1–3). About
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October 5, 2010:1196–204 Coenzyme Q10 and Outcomes in Heart Failurene-half of coenzyme Q10 is ingested in dietary fat, and the
emainder is synthesized endogenously through the meval-
nate pathway, which is blocked by statins (1–3).
Coenzyme Q10 deficiency has been associated with my-
pathy, and there has been concern that statins might cause
eripheral and cardiac muscle dysfunction by reducing
oenzyme Q10 production (4,5). In theory, coenzyme Q10
epletion could lead to muscle energy starvation (a partic-
lar concern in the failing heart [6]) and oxidative damage
o myocytes. These theoretical concerns have been coupled
ith the observation that low cholesterol is associated with
worse prognosis in heart failure (7), forming the basis of
rticles in the lay press and on the web that have suggested
hat statins might be dangerous in heart failure. In practice,
owever, the role of coenzyme Q10 in the effect of statins on
uscle function (if any) is uncertain, as is the association
etween plasma coenzyme Q10 concentration and clinical
utcomes in cardiovascular disease (8–18). In 1 recent
tudy, however, low plasma coenzyme Q10 concentration
as found to be an independent predictor of mortality in
atients hospitalized with heart failure (18).
Because of the concerns alluded to above, the U.S. Food
nd Drug Administration requested that we measure plasma
oenzyme Q10 concentration in a subset of the patients with
schemic systolic heart failure enrolled in the CORONA
Controlled Rosuvastatin Multinational Study in Heart
ailure) trial. In this pre-specified substudy, we investigated
he effect of statin therapy on coenzyme Q10 concentration,
s well as the relationship between coenzyme Q10 and fatal
nd nonfatal cardiovascular events (19,20).
ethods
atients. The design and principal findings of the
ORONA study have been reported in detail (19,20).
atients 60 years of age with chronic New York Heart
ssociation (NYHA) functional class II to IV heart failure
f investigator-reported ischemic etiology and a left ventric-
lar ejection fraction (LVEF) of 40% (0.35 if NYHA
unctional class II) were eligible, provided that the investi-
ator believed they did not need treatment with a
holesterol-lowering drug.
Exclusion criteria included recent cardiovascular events,
rocedures, or operations (or planned procedures or opera-
ions); acute or chronic liver disease or alanine aminotrans-
erase 2 times the upper limit of normal (ULN); serum
reatinine 220 mol/l (2.49 mg/dl); chronic muscle
isease or unexplained creatine kinase 2.5 times ULN;
hyroid-stimulating hormone 2 times ULN; or any other
ondition substantially reducing life expectancy.
tudy procedures. The trial was approved by ethics com-
ittees of participating hospitals, and patients provided
ritten informed consent. Patients were allocated, equally,
o 10 mg of rosuvastatin or matching placebo, once daily.
e measured serum creatinine, creatine kinase, thyroid-timulating hormone, alanine aminotransferase, high- sensitivity C-reactive protein, and
ipid/lipoproteins (total, low-
ensity lipoprotein [LDL] choles-
erol, high-density lipoprotein
holesterol, triglycerides, and apo-
ipoprotein [apo] A-1 and B) at
aseline in all 5,011 patients.
After the study started, the
rotocol was amended to include
easurement of N-terminal pro–
-type natriuretic peptide (NT-
roBNP), which was available in
,664 (73%) patients. All measure-
ents, except thyroid-stimulating
ormone, were repeated at 3
onths. In a pre-specified substudy, coenzyme Q10 was
easured in 1,191 patients using a high-performance
iquid chromatography method after extraction of serum
nto hexane and using vitamin K1 as an internal standard.
he reference range is 0.34 to 2.54 g/ml (0.39 to 2.94
mol/l).
All blood samples were nonfasting and were analyzed at
central laboratory (Medical Research Laboratories,
aventem, Belgium). The LDL was directly measured.
oenzyme Q10 was analyzed on fresh samples sent at
efrigerated temperature by overnight mail to the central
aboratory.
tudy outcomes and definitions. The primary outcome
as the composite of cardiovascular mortality, nonfatal
yocardial infarction, or nonfatal stroke, analyzed as time
o the first event. The secondary outcomes were (in listed
rder): all-cause mortality, any coronary event (defined as
udden death, fatal or nonfatal myocardial infarction, per-
utaneous coronary intervention, coronary artery bypass
raft surgery, ventricular defibrillation by an implantable
ardioverter-defibrillator, resuscitation from cardiac arrest,
r hospitalization for unstable angina), cardiovascular mor-
ality (cause-specific cardiovascular death was also ana-
yzed), and number (episodes) of hospitalizations (for car-
iovascular causes, unstable angina, and worsening heart
ailure). The present report focuses on the primary end
oint, total mortality, the coronary end point, and hospital-
zations (all-cause, cardiovascular cause, and worsening
eart failure). We also included the additional post-hoc
omposite outcome of death from any cause or hospitaliza-
ion for worsening heart failure (analyzed as time to first
vent) because of previously expressed concerns that coen-
yme Q10 deficiency might cause worsening heart failure,
eading to increased risk of hospital admission and death.
e conducted further post-hoc analyses of patients hospi-
alized for all causes, cardiovascular causes, worsening heart
ailure, and noncardiovascular causes (analyzed as time to
rst event). The definition and adjudication of all outcomes
ave been described in detail previously (19,20). As the
esult of a protocol amendment adopted 15 months after the
Abbreviations
and Acronyms
apo  apolipoprotein
LDL  low-density
lipoprotein
LVEF  left ventricular
ejection fraction
NT-proBNP  N-terminal
pro–B-type natriuretic
peptide
NYHA  New York Heart
Association
ULN  upper limit of
normaltart of the trial, patients also completed a questionnaire
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Coenzyme Q10 and Outcomes in Heart Failure October 5, 2010:1196–204bout muscle symptoms at each study visit and had a
easurement of creatine kinase at 6 and 15 months after
andomization, yearly thereafter, and at the last study visit
20). Patients were asked 2 questions: whether they had any
uscular pain since the previous visit, and whether they had
uscular pain at the present visit.
nalysis plan. We addressed 2 main questions: 1) Was
aseline serum coenzyme Q10 concentration associated with
he range of clinical outcomes described above? 2) Did
reatment with rosuvastatin increase the risk of any of the
escribed outcomes in patients with a low serum coenzyme
10 concentration?
To answer the first question, we examined clinical charac-
eristics and outcomes in patients divided according to tertile of
aseline coenzyme Q10 concentration, and we entered baseline
oenzyme Q10 (as a continuous variable) in a series of extensive
ultivariable models previously developed in the CORONA
tudy population (21). These models had been built for the
ther mortality–morbidity composite outcomes listed in the
revious text, in addition to all-cause mortality.
To answer the second question, we examined the effect of
osuvastatin compared with placebo in each of the baseline
oenzyme Q10 tertiles, looking at both the unadjusted treat-
ent effect and effect of treatment adjusted for age group
75/75 years); sex (female/male); baseline LVEF (0.25/
0.25) and NYHA functional class (III to IV/II); beta-blocker
se (yes/no); total cholesterol (6.0/6.0 mmol/l); and history
f myocardial infarction (yes/no) or hypertension (yes/no), as
re-specified in the main CORONA study analysis plan. Tests
or interaction between treatment effect and baseline coenzyme
10 value were carried out as described in the following text.
tatistical analysis. For continuous variables, differences in
aseline variables between the patients in each coenzyme
10 tertile were tested with the Student t test (NT-proBNP
ith the Wilcoxon rank-sum test) and for categorical
ariables with the Fisher exact test. For comparison of
ertiles, we used the Jonckheere-Terpstra test (for continu-
us variables) and the Cochran-Armitage trend test (for
ategorical variables). The multivariable analyses to which
aseline coenzyme Q10 concentration was added as a con-
inuous variable have been described in detail previously
21). The 8 most important demographic and clinical
ariables included age, sex, LVEF, NYHA functional class,
eart rate, body mass index, history of diabetes mellitus, and
ntermittent claudication. The 2 most important biochem-
cal variables were serum creatinine concentration and
poA-1 concentration. The log concentration of the neuro-
umoral marker NT-proBNP was the single most impor-
ant predictor of all outcomes (21).
Cox’s proportional hazards models (unadjusted and ad-
usted) were used to calculate hazard ratios and 95%
onfidence intervals (SAS version 8.2, SAS Institute, Cary,
orth Carolina) in all patients and in each coenzyme Q10
oncentration tertile separately. The adjusted Cox regres-
ion model incorporated randomized treatment and the mariables described earlier. Similar Cox analyses were per-
ormed to compare cardiovascular risk between NT-
roBNP tertile 1 and tertile 3 in the placebo group.
Total number (episodes) of hospital admissions were
nalyzed using a permutation test. Tests for interaction
etween treatment effect and coenzyme Q10 tertile, for each
utcome, were carried out using a Cox regression analysis
ith the following covariates, treatment as 0/1, coenzyme
10 tertile as 0/1, and treatment*coenzyme Q10 tertile
interaction) as 0/1. We also analyzed interaction by treat-
ent with coenzyme Q10 as a continuous variable.
esults
he baseline characteristics of the 1,191 patients with
measurement of coenzyme Q10 are shown in Table 1
all patients and by tertiles of baseline coenzyme Q10
oncentration).
aseline characteristics by tertile of coenzyme Q10
oncentration. Patients in the lowest coenzyme Q10 con-
entration tertile (tertile 1) were, on average, older, in a
igher NYHA functional class, had more atrial fibrillation/
utter, had lower plasma lipids, and had a lower LVEF and
stimated glomerular filtration rate compared with those in
he highest tertile. NT-proBNP concentration was also
ignificantly higher in patients in the lowest coenzyme Q10
ertile compared with the highest tertile.
ffect of rosuvastatin on serum LDL and plasma coenzyme
10 concentration (change from baseline to 3-month
ollow-up visit). In the whole group of patients studied,
DL declined from a mean of 142 mg/dl at baseline to
6 mg/dl at 3 months with rosuvastatin but did not change
n the placebo group: 141 mg/dl at baseline and 141 mg/dl
t 3 months (48% net difference; p  0.0001). The
orresponding net difference in tertiles of coenzyme Q10 was
1%, 48%, and 45% (tertiles 1, 2, and 3, respectively).
Overall, coenzyme Q10 also declined at 3 months with
osuvastatin but did not change in the placebo group
39% net difference; p  0.0001) (Table 2). Rosuvastatin
educed plasma coenzyme Q10 concentration in all 3 ter-
iles (Table 2).
linical outcomes in the placebo group according to
aseline coenzyme Q10 tertile. In patients treated with
lacebo, the risk of the pre-defined primary outcome of
ardiovascular death, myocardial infarction, or stroke (ex-
ressed as patients experiencing an event per 100 person-years
f follow-up) was numerically highest in patients in the lowest
oenzyme Q10 tertile, intermediate in the middle tertile, and
owest in patients in the highest coenzyme Q10 tertile (Table 3).
he same relationship was seen between coenzyme Q10 tertile
nd mortality, the other composite outcomes, and hospitaliza-
ions (Table 4). However, risk was not significantly higher in
oenzyme Q10 tertile 1, compared with tertile 3, after adjust-
ent for other prognostic variables (Table 5).
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October 5, 2010:1196–204 Coenzyme Q10 and Outcomes in Heart Failuressociation between coenzyme Q10 concentration, mortality,
nd other clinical outcomes: multivariable analysis.
hen entered as a continuous variable in our previously
escribed multivariable models, coenzyme Q10 was not an
ndependent predictor of all-cause mortality (Table 6), or
ny of the other mortality–morbidity outcomes examined
haracteristics of Patients in Each Tertile According to Baseline CTable 1 Characteristics of Patients in Each Tertile According t
Variables
All With Coenzyme Q10
(n  1,191) (
Demographics
Age, yrs 73.2 (7.0) 74.
Age 75 yrs, n (%) 531 (45) 21
Female sex, n (%) 239 (20) 7
NYHA functional class, n (%)
II 559 (47) 16
III 621 (52) 22
IV 11 (0.9)
Ejection fraction 0.295 (0.069) 0.28
BMI, kg/m2 27.0 (4.2) 26.
Systolic blood pressure, mm Hg 129 (18) 12
Diastolic blood pressure, mm Hg 75 (9.3) 7
Heart rate, beats/min 71 (11) 7
Medical history, n (%)
Myocardial infarction 716 (60) 24
Angina pectoris* 868 (73) 27
CABG or PTCA/PCI 454 (38) 14
Hypertension 593 (50) 19
Diabetes mellitus 329 (28) 11
AF or atrial flutter† 195 (16) 7
Stroke 101 (8.5) 3
Intermittent claudication 158 (13) 5
Laboratory measurements
Total cholesterol, mmol/l‡ 5.52 (1.10) 4.9
LDL cholesterol, mmol/l‡ 3.66 (0.92) 3.2
HDL cholesterol, mmol/l‡ 1.20 (0.35) 1.1
ApoA-1, g/l 1.49 (0.28) 1.4
ApoB, g/l 1.31 (0.30) 1.1
Triglycerides, mmol/l§ 2.33 (1.50) 1.8
Serum creatinine, mol/l 120 (30) 12
Serum creatinine 130 mol/l, n (%) 350 (29) 14
eGFRMDRD, ml/min/1.73 m
2 BSA 56 (14) 5
NT-proBNP, pmol/l¶ 145 (54–314) 20
hsCRP, mg/l 3.7 (1.6–7.9) 3.
Coenzyme Q10, g/ml# 0.74 (0.56–0.99) 0.4
Medication, n (%)
Loop diuretic 833 (70) 29
Aldosterone antagonist 363 (31) 13
ACE inhibitor or ARB 1,094 (92) 36
Beta-blocker 876 (74) 27
Digitalis glycoside 366 (31) 11
Antiarrhythmic therapy 130 (11) 5
atients are split into 3 equal groups (tertiles) according to baseline coenzyme Q10 concentration
oenzyme Q10, NT-proBNP, and hsCRP as median (interquartile range); binary and discrete variab
8.67. §To convert to mg/dl, multiply by 88.5 mol/l. To convert to mg/dl, multiply by 0.0113. ¶
lacebo- and 415 rosuvastatin-treated patients. #To convert mol/l, multiply by 1.158.
ACE  angiotensin-converting enzyme; AF  atrial fibrillation; Apo  apolipoprotein; ARB  an
ypass graft surgery; eGFR estimated glomerular filtration rate; HDL high-density lipoprotein;
isease; NT-proBNP N-terminal pro–B-type natriuretic peptide; NYHA New York Heart Associatidata not shown). tssociation between rosuvastatin treatment and clinical
utcomes according to baseline coenzyme Q10 tertile.
OTAL MORTALITY AND COMPOSITE MORTALITY–
ORBIDITY END POINTS. The hazard ratio estimating the
reatment effect for all 4 time-to-first-event end points was1.0
n coenzyme Q10 tertile 1 and1.0 in tertiles 2 and 3, although
me Q10 Concentrationeline Coenzyme Q10 Concentration
1
0)
Tertile 2
(n  387)
Tertile 3
(n  404)
p Value for Trend
Across Tertiles
73.3 (6.9) 71.5 (7.1) 0.0001
176 (46) 137 (34) 0.0001
82 (21) 79 (20) 0.2
0.076
194 (50) 196 (49)
190 (49) 203 (50)
3 (0.8) 5 (1.2)
3) 0.297 (0.067) 0.302 (0.066) 0.0047
27.1 (4.2) 27.6 (4.2) 0.0001
130 (18) 130 (17) 0.19
75 (9.5) 76 (8.6) 0.027
71 (11) 71 (12) 0.20
243 (63) 233 (58) 0.20
285 (74) 306 (76) 0.039
144 (37) 169 (42) 0.055
190 (49) 210 (52) 0.20
104 (27) 113 (28) 0.20
57 (15) 62 (15) 0.030
39 (10) 25 (6.2) 0.12
57 (15) 46 (11) 0.20
) 5.57 (0.88) 6.03 (1.05) 0.0001
) 3.74 (0.82) 3.97 (0.96) 0.0001
) 1.21 (0.34) 1.23 (0.39) 0.14
) 1.50 (0.26) 1.57 (0.30) 0.0001
) 1.33 (0.25) 1.45 (0.29) 0.0001
) 2.16 (1.10) 3.00 (2.10) 0.0001
117 (30) 117 (27) 0.0059
96 (25) 106 (26) 0.0008
57 (14) 57 (14) 0.0008
416) 125 (52–255) 107 (46–250) 0.0001
10.2) 3.6 (1.3–7.9) 3.8 (1.65–7.3) 0.20
–0.57) 0.74 (0.66–0.82) 1.10 (0.97–1.37) NA
268 (69) 267 (66) 0.0094
118 (31) 112 (28) 0.089
361 (93) 370 (92) 0.20
289 (75) 308 (76) 0.037
103 (27) 149 (37) 0.0099
33 (8.5) 39 (9.7) 0.028
shows other baseline characteristics in these tertiles. Continuous variables given as mean (SD),
n as n (%). *Past or current. †Current on electrocardiography. ‡To convert to mg/dl, multiply by
ert to pg/ml, multiply by 8.457. In patients with coenzyme Q10, NT-proBNP was measured in 422
in-receptor blocker; BMI  body mass index; BSA  body surface area; CABG  coronary artery
high sensitivity C reactive protein; LDL low-density lipoprotein; MDRDmodified diet in renal
 percutaneous coronary intervention; PTCA percutaneous transluminal coronary angiography.oenzyo Bas
Tertile
n  40
7 (7.1)
8 (55)
8 (20)
9 (42)
8 (57)
3 (0.8)
7 (0.07
2 (4.1)
9 (18)
4 (9.8)
1 (11)
0 (60)
7 (69)
1 (35)
3 (48)
2 (28)
6 (19)
7 (9.3)
5 (14)
5 (0.96
6 (0.84
7 (0.30
1 (0.25
7 (0.27
3 (0.91
4 (32)
8 (37)
4 (15)
6 (85–
8 (1.6–
9 (0.39
8 (75)
3 (33)
3 (91)
9 (70)
4 (29)
8 (15)
. Table
les give
To conv
giotenshe 95% confidence intervals overlapped 1.0 in all subgroups
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Coenzyme Q10 and Outcomes in Heart Failure October 5, 2010:1196–204Table 3). There was no significant interaction between treatment
ffect and coenzyme Q10 tertile, with p values ranging from 0.14
primary end point) to 0.26 (coronary end point) for the 4 end
oints (Table 3). Corresponding p values with coenzyme Q10
ncluded as a continuous variable were between 0.49 (coronary end
oint) and 0.95 (primary end point).
OSPITALIZATIONS. A similar picture was seen when the
ost-hoc outcome of number of patients hospitalized (analyzed
s time to first hospitalization) was examined, with rosuvastat-
n:placebo hazard ratios 1 in coenzyme Q10 tertile 1 for
aseline and 3-Month Follow-Up Values for Coenzyme Q10Table 2 Baseline and 3-Month Follow-Up Values for Coenzyme
Subgroups
Baseline
Median (IQR)
3-Month Follow-
Median (IQR)
Tertile 1
Placebo (n  199/181)† 0.48 (0.39–0.56) 0.58 (0.47–0.73
Rosuvastatin (n  201/181) 0.49 (0.39–0.57) 0.35 (0.26–0.45
Tertile 2
Placebo (n  204/187) 0.73 (0.66–0.80) 0.70 (0.55–0.87
Rosuvastatin (n  183/176) 0.75 (0.68–0.82) 0.46 (0.34–0.59
Tertile 3
Placebo (n  197/184) 1.11 (0.97–1.31) 0.93 (0.73–1.14
Rosuvastatin (n  207/184) 1.10 (0.97–1.37) 0.53 (0.40–0.70
All patients
Placebo (n  600/552) 0.72 (0.56–0.97) 0.72 (0.54–0.95
Rosuvastatin (n  591/551) 0.75 (0.56–0.99) 0.44 (0.33–0.59
aseline and 3-month follow-up values for coenzyme Q10 in g/ml (to convert to mol/l, multiply
or % net difference between rosuvastatin and placebo in the 3 tertiles of baseline coenzyme Q10 a
umbers.
ime-to-First Event End Points in All Patients Randomized and in Pnto 3 Equal Groups (Tertiles) According to Baseline Coenzyme Q10Table 3 Time- o-First Event End oints in All Patients RandomiInto 3 Equal Groups (Tertiles) According to Baseline C
End Point
Placebo
n (Rate)*
Rosuvastatin
n (Rate)*
Primary end point
Tertile 1 59 (12.8) 72 (16.8)
Tertile 2 56 (11.4) 41 (8.8)
Tertile 3 53 (10.4) 51 (9.7)
All randomized 732 (12.3) 692 (11.4)
All-cause mortality
Tertile 1 67 (14.1) 78 (17.1)
Tertile 2 60 (11.8) 44 (9.2)
Tertile 3 51 (9.6) 50 (9.2)
All randomized 759 (12.2) 728 (11.6)
Coronary end point
Tertile 1 45 (9.9) 54 (12.8)
Tertile 2 46 (9.5) 34 (7.4)
Tertile 3 45 (9.1) 48 (9.5)
All randomized 588 (10.0) 554 (9.3)
All-cause mortality or hospitalization for
worsening HF¶
Tertile 1 86 (19.9) 96 (23.4)
Tertile 2 79 (17.0) 59 (13.5)
Tertile 3 76 (15.6) 66 (13.1)
All randomized 1,112 (20.5) 1,056 (19.1)
Events per 100 patient-years of follow-up. †Cox unadjusted (Cox adjusted within parentheses). ‡
oenzyme Q10 subgroups. Cardiovascular death or nonfatal myocardial infarction or nonfatal stroke (tim
CI  confidence interval; HF  heart failure.ospitalizations for any cause, cardiovascular causes, worsening
eart failure, and noncardiovascular causes (Table 4). All
orresponding hazard ratios in tertiles 2 and 3 were 1. As
ith all-cause mortality and the composite mortality–
orbidity outcomes, there was no statistically significant in-
eraction between treatment and coenzyme Q10 tertile, al-
hough the p value for cardiovascular hospitalization was 0.052.
By contrast, the total number (episodes) of hospitaliza-
ions (a pre-specified secondary end point) for admissions
ue to any cause, cardiovascular causes, and heart failure
Absolute Median
Change
Net Median
Change*
% Median
Change p Value*
0.25 0.0001
0.12 25.4
0.13 27.3
0.27 0.0001
0.03 4.8
0.30 40.5
0.0001
0.22 0.35 20.3
0.57 53.1
0.29 0.0001
0.02 2.7
0.31 41.9
58): median (interquartile range [IQR]), absolute median change, % median change, and p value
l patients with a coenzyme Q10 measurement. *Rosuvastatin minus placebo. †Baseline/follow-up
ts Splitcentrationnd in Patients Split
me Q10 Concentration
zard Ratio† 95% CI†
Subgroup
p Value‡
Interaction
p Value§
0.14
.30 (1.30) 0.92–1.83 (0.92–1.84) 0.13 (0.14)
.78 (0.81) 0.52–1.17 (0.54–1.21) 0.20 (0.20)
.94 (0.88) 0.64–1.38 (0.60–1.29) 0.20 (0.20)
.92 (0.92) 0.83–1.02 (0.83–1.02) 0.12 (0.10)
0.24
.21 (1.19) 0.87–1.68 (0.86–1.66) 0.20 (0.20)
.79 (0.82) 0.54–1.17 (0.56–1.22) 0.20 (0.20)
.96 (0.90) 0.65–1.42 (0.61–1.34) 0.20 (0.20)
.95 (0.95) 0.86–1.05 (0.86–1.05) 0.20 (0.20)
0.26
.27 (1.28) 0.86–1.89 (0.86–1.90) 0.20 (0.20)
.78 (0.81) 0.50–1.22 (0.52–1.26) 0.20 (0.20)
.06 (1.04) 0.70–1.59 (0.69–1.56) 0.20 (0.20)
.92 (0.92) 0.82–1.04 (0.82–1.04) 0.18 (0.17)
0.17
.17 (1.16) 0.88–1.57 (0.87–1.56) 0.18 (0.20)
.81 (0.82) 0.58–1.13 (0.58–1.15) 0.20 (0.20)
.84 (0.80) 0.60–1.17 (0.57–1.11) 0.20 (0.18)
.93 (0.93) 0.86–1.02 (0.85–1.01) 0.11 (0.09)
adjusted Cox, p value from log-rank test, for adjusted from Cox. §By treatment comparing the 3Q10
Up
)
)
)
)
)
)
)
)
by 1.1atienCozed a
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1
0
0
0
1
0
0
0
1
0
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enerally numerically fewer in the rosuvastatin group in
ertiles 2 and 3 (Table 4).
utcomes in the lowest coenzyme Q10 tertile (tertile 1)
y treatment assignment. Although there were no sta-
istically significant differences between the treatment
otal Number of Patients Hospitalized and Total Number of HospitalizaTable 4 Total Number of Patients Hospitalized and Total Number
Type of Hospitalization Type of End Point
Placebo
n (Rate)*
Rosuvastat
n (Rate)
All-cause
Tertile 1 Patients 119 (37.2) 137 (49.6)
Hospitalizations 293 (61.8) 296 (65.3)
Tertile 2 Patients 117 (33.2) 103 (30.2)
Hospitalizations 279 (55.0) 215 (45.2)
Tertile 3 Patients 115 (32.5) 117 (32.1)
Hospitalizations 271 (51.1) 295 (54.3)
Cardiovascular
Tertile 1 Patients 85 (23.2) 98 (28.9)
Hospitalizations 174 (36.7) 169 (37.3)
Tertile 2 Patients 87 (21.5) 67 (16.9)
Hospitalizations 165 (32.5) 102 (21.4)
Tertile 3 Patients 92 (22.3) 78 (17.5)
Hospitalizations 166 (31.3) 153 (28.2)
Worsening heart failure
Tertile 1 Patients 45 (10.4) 44 (10.7)
Hospitalizations 77 (16.2) 69 (15.2)
Tertile 2 Patients 45 (9.7) 30 (6.9)
Hospitalizations 75 (14.8) 38 (8.0)
Tertile 3 Patients 42 (8.6) 36 (7.4)
Hospitalizations 60 (11.3) 58 (10.7)
Noncardiovascular
Tertile 1 Patients 74 (19.0) 81 (22.7)
Hospitalizations 119 (25.1) 127 (28.0)
Tertile 2 Patients 67 (15.8) 68 (17.5)
Hospitalizations 114 (22.5) 113 (23.7)
Tertile 3 Patients 62 (14.2) 75 (17.4)
Hospitalizations 105 (19.8) 142 (26.2)
Rate is number of events per 100 patient-years of follow-up. †The p value for number of patients
coenzyme Q10 subgroups for time to first hospitalization (number of patients variable).
CI  confidence interval; NA  not applicable or not analyzed.
Comparison of Risk During Follow-Up of Patientenzyme Q10 Tertile 1 Compared to Tertile 3 inTable 5 Comparison of Risk During Fo low-UCoenzyme Q10 Tertile 1 Compared t
End Point
Tertile 1
Hazard
All-cause mortality 1.50 (1
Hospitalizations
All-cause 1.13 (1
Cardiovascular cause 1.04 (0
Worsening HF 1.20 (0
Noncardiovascular cause 1.32 (1
Combined end points
Primary end point 1.25 (0
Coronary end point 1.09 (0
All-cause mortality/HF hospitalization 1.27 (1
*Cox unadjusted with Cox adjusted within parentheses. For number of
follow-up, see Tables 3 and 4.
Abbreviations as in Table 3.roups in the coenzyme Q10 tertile 1, there was an excess
f 11 deaths in the rosuvastatin group compared with
lacebo group (Table 3). There were 5 extra cardiovas-
ular deaths, 3 of which were due to myocardial infarc-
ion and 2 of which were sudden. There were 6 extra
oncardiovascular deaths. The number of deaths due to
(Episodes) in the 3 Baseline Coenzyme Q10 Tertilesspitalizations (Episodes) in the 3 Baseline Coenzyme Q10 Tertiles
Hazard Ratio 95% CI
Subgroup
p Value†
Interaction
p Value‡
0.10
1.32 (1.32) 1.03–1.69 (1.03–1.69) 0.027 (0.030)
NA NA 0.20
0.91 (0.90) 0.70–1.19 (0.69–1.18) 0.20 (0.20)
NA NA 0.20
0.99 (0.98) 0.77–1.29 (0.76–1.27) 0.20 (0.20)
NA NA 0.20
0.052
1.24 (1.23) 0.93–1.66 (0.92–1.64) 0.14 (0.17)
NA NA 0.20
0.79 (0.77) 0.58–1.09 (0.56–1.06) 0.15 (0.11)
NA NA 0.032
0.79 (0.76) 0.58–1.06 (0.56–1.02) 0.12 (0.069)
NA NA 0.20
0.51
1.03 (1.02) 0.68–1.56 (0.67–1.55) 0.20 (0.20)
NA NA 0.20
0.72 (0.69) 0.45–1.14 (0.43–1.10) 0.16 (0.12)
NA NA 0.047
0.83 (0.78) 0.53–1.29 (0.50–1.22) 0.20 (0.20)
NA NA 0.20
0.91
1.20 (1.20) 0.97–1.64 (0.87–1.65) 0.26 (0.27)
NA NA NA
1.11 (1.14) 0.79–1.55 (0.81–1.61) 0.55 (0.45)
NA NA NA
1.23 (1.22) 0.88–1.72 (0.87–1.71) 0.23 (0.25)
NA NA NA
g-rank, for total number of hospitalizations from permutation test. ‡By treatment comparing the
Placebo Group*Patients in
rtile 3 in the Placebo Group*
Tertile 1 vs. 3
95% CI
Tertile 1 vs. 3
p Value
1.04–2.16 (0.79–1.72) 0.030 (0.44)
0.88–1.46 (0.82–1.42) 0.35 (0.58)
0.78–1.40 (0.70–1.30) 0.79 (0.76)
0.79–1.83 (0.63–1.54) 0.39 (0.94)
0.95–1.86 (0.93–1.93) 0.10 (0.11)
0.86–1.82 (0.63–1.38) 0.23 (0.72)
0.72–1.65 (0.58–1.39) 0.67 (0.61)
0.94–1.74 (0.76–1.46) 0.12 (0.77)
ints and rate expressed as number of events per 100 patient-years oftionsof Ho
in
from los inthep of
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vs. 3
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oenzyme Q10 tertile 1.
Looking at nonfatal events, there were 18 more patients
ospitalized at least once for any reason in the rosuvastatin
roup compared with placebo group; however, only 3 more
pisodes of hospital admissions. The equivalent numbers for
ardiovascular hospitalization were13 and5. One fewer
rognostic Model for Testing Baselineoenzyme Q10 Q as Risk Factor for Total MortalityTable 6 Prognostic Model for Testing BaselineCoenzyme Q10 Q as Risk Factor for Total Mortality
Variables HR 95% CI Wald p Value
Step 1
Placebo group
Ejection fraction*100 0.96 0.94–0.98 12.0 0.0007
NYHA functional class 1.99 1.33–2.98 11.0 0.0009
Age/10 yrs 1.57 1.17–2.10 9.1 0.0026
BMI, kg/m2 0.97 0.92–1.02 1.9 0.17
Diabetes mellitus 1.34 0.88–2.04 1.9 0.17
Female sex 0.76 0.46–1.26 1.1 0.29
Intermittent claudication 1.21 0.70–2.10 0.5 0.49
Heart rate/10 beats/min 1.05 0.89–1.24 0.4 0.54
Coenzyme Q10, g/ml 0.86 0.49–1.50 0.3 0.59
Rosuvastatin group
Age/10 yrs 1.75 1.30–2.35 14.0 0.0002
Ejection fraction*100 0.96 0.93–0.99 9.2 0.0025
Female sex 0.49 0.28–0.85 6.5 0.011
Coenzyme Q10, g/ml 0.55 0.31–0.97 4.3 0.039
Diabetes mellitus 1.57 1.02–2.42 4.2 0.040
BMI, kg/m2 0.95 0.91–1.01 3.2 0.074
NYHA functional class 1.37 0.91–2.07 2.3 0.13
Heart rate/10 beats/min 1.09 0.91–1.31 0.9 0.33
Intermittent claudication 1.10 0.66–1.82 0.1 0.72
Step 2
Placebo group
Ejection fraction*100 0.96 0.94–0.99 10.0 0.0015
NYHA functional class 1.87 1.24–2.83 8.8 0.0031
Age/10 yrs 1.49 1.10–2.01 6.6 0.010
BMI, kg/m2 0.96 0.91–1.01 2.2 0.14
Serum creatinine/10 mol/l 1.05 0.98–1.11 2.0 0.15
Diabetes mellitus 1.28 0.83–1.98 1.3 0.26
Intermittent claudication 1.22 0.70–2.11 0.5 0.48
Heart rate/10 beats/min 1.06 0.90–1.24 0.4 0.52
ApoA-1, g/l 0.79 0.37–1.72 0.3 0.56
Female sex 0.87 0.51–1.49 0.3 0.61
Coenzyme Q10, g/ml 0.91 0.52–1.60 0.1 0.74
Rosuvastatin group
Age/10 yrs 1.60 1.18–2.16 9.0 0.0027
Ejection fraction*100 0.96 0.93–0.99 8.5 0.0035
Serum creatinine/10 mol/l 1.08 1.02–1.15 6.1 0.013
BMI, kg/m2 0.94 0.90–1.00 4.6 0.032
Diabetes mellitus 1.55 1.00–2.41 3.9 0.049
ApoA-1, g/l 0.48 0.21–1.08 3.2 0.076
Female sex 0.63 0.35–1.12 2.5 0.12
Coenzyme Q10, g/ml 0.64 0.36–1.13 2.4 0.13
Heart rate/10 beats/min 112 0.93–1.35 1.5 0.22
NYHA functional class 1.27 0.83–1.93 1.2 0.27
Intermittent claudication 1.06 0.63–1.77 0.05 0.82
Continuedatient in the rosuvastatin group than the placebo group was aospitalized for worsening heart failure (and there were 8
ewer admissions for heart failure in the rosuvastatin group).
here were 9 more nonfatal myocardial infarctions in the
osuvastatin group in coenzyme Q10 tertile 1.
hange in NYHA functional class. The mean change in
YHA functional class from baseline to last study visit in
oenzyme Q10 tertile 1 was 0.085 in the placebo group
nd 0.035 in the rosuvastatin group (p  0.44). The
quivalent changes in tertile 2 were 0.015 and 0.104
p  0.14), and in tertile 3, they were 0.122 and 0.145
p  0.75).
uscle symptoms and creatine kinase. Similar numbers
f patients in each coenzyme Q10 tertile reported muscular
ain on questioning, and this was also the case for placebo-
reated compared with rosuvastatin-treated patients. For the
uestion about muscular pain since the previous visit, the
roportions in the placebo group were 7.5%, 10.3%, and
.1% (tertiles 1, 2, and 3, respectively), and in the rosuvas-
atin group, they were 8.5%, 9.8%, and 6.3%, respectively.
orresponding figures for the question about muscular pain
t the current visit, were 6.0%, 7.4%, and 6.6% (placebo)
ontinuedTable 6 Continued
Variables HR 95% CI Wald p Value
Step 3
Placebo group
Log NT-proBNP 1.73 1.41–2.11 28.0 0.0001
NYHA functional class 1.63 1.07–2.48 5.2 0.023
Age/10 yrs 1.40 1.04–1.88 4.8 0.028
Ejection fraction*100 0.98 0.05–1.00 2.7 0.10
Female sex 0.75 0.44–1.30 1.0 0.31
Intermittent claudication 1.21 0.70–2.10 0.5 0.50
ApoA-1, g/l 0.82 0.39–1.75 0.3 0.61
Serum creatinine/10 mol/l 0.9 0.93–1.05 0.2 0.66
Coenzyme Q10, g/ml 1.13 0.64–2.01 0.2 0.67
Diabetes mellitus 1.10 0.71–1.70 0.2 0.68
Heart rate/10 beats/min 1.02 0.86–1.20 0.03 0.87
BMI, kg/m2 1.00 0.95–1.05 0.0 0.92
Rosuvastatin group
Log NT-proBNP 1.81 1.46–2.24 29 0.0001
ApoA-1, g/l 0.45 0.20–1.01 3.8 0.053
Age/10 yrs 1.36 0.99–1.87 3.7 0.056
Ejection fraction*100 0.97 0.95–1.00 3.6 0.058
Female sex 0.58 0.33–1.03 3.5 0.063
Diabetes mellitus 1.44 0.93–2.23 2.6 0.10
BMI, kg/m2 0.96 0.91–1.01 2.4 0.11
Heart rate/10 beats/min 1.10 0.91–1.33 1.0 0.31
Serum creatinine/10 mol/l 1.03 0.96–1.10 0.8 0.37
Coenzyme Q10, g/ml 0.82 0.45–1.47 0.5 0.50
NYHA functional class 1.14 0.75–1.74 0.4 0.55
Intermittent claudication 0.96 0.57–1.62 0.0 0.88
rognostic model for testing baseline coenzyme Q10 Q as a risk factor for total mortality in 3 steps
ccording to the CORONA model: step 1 including the 8 most important demographic and clinical
ariables, step 2 adding the 2 most important biochemical variables, and step 3 adding also the
ost important predictor of all outcomes, the neurohumoral marker NT-proBNP (see Methods
ection and Wedel et al. [21]). Placebo group, 114 deaths, 420 patients; rosuvastatin group, 108
eaths, 411 patients. In each step, variables are ranked after Wald value.
HR  hazard ratio; other abbreviations as in Table 1.nd 6.0%, 6.0%, and 4.3% (rosuvastatin). Only 1 patient had
a
(
P
p
d
i
i
2
b
w
o
D
W
c
m
p
w
e
f
c
e
m
c
u
a
a
T
g
i
r
s
a
d
t
s
o
s
Q
i
f
v
p
(
d
b
p
h
r
d
Q
i
s
m
e
h
Q
i
p
c
s
f
c
Q
h
t
c
t
i
t
c
a
b
o
c
v
d
“
a
d
t
o
d
t
a
i
t
i
i
fi
r
c
d
c
C
A
a
b
i
d
p
w
a
e
1203JACC Vol. 56, No. 15, 2010 McMurray et al.
October 5, 2010:1196–204 Coenzyme Q10 and Outcomes in Heart Failurecreatine kinase value 10 times ULN during follow-up
randomized to placebo).
remature discontinuation of study drug. The number of
atients in coenzyme Q10 tertile 1 who discontinued study
rug for any reason was 50 (30 because of an adverse event)
n the placebo group and 44 (24 because of an adverse event)
n the rosuvastatin group. The equivalent numbers in tertile
were 54 (35 because of an adverse event) and 38 (19
ecause of an adverse event), and in tertile 3, the numbers
ere 52 (31 because of an adverse event) and 44 (28 because
f an adverse event).
iscussion
e found that patients with a lower serum coenzyme Q10
oncentration at baseline were older and had evidence of
ore severe heart failure. In particular, several powerful
redictors of poor prognosis were more prevalent in patients
ith a lower coenzyme Q10, including lower LVEF and
stimated glomerular filtration rate and higher NYHA
unctional class and NT-proBNP concentration. Lower
oenzyme Q10 was also associated with higher age and, as
xpected, lower lipid levels (lower lipid levels are also a
arker of poor prognosis in heart failure). Although lower
oenzyme Q10 was associated with a higher risk of death in
nadjusted analyses, coenzyme Q10 concentration was not
n independent predictor of mortality in a multivariable
nalysis (or an independent predictor of any other outcome).
his finding differs from that of the 1 other study investi-
ating the relationship between coenzyme Q10 and mortal-
ty in patients with heart failure (18).
There are several important differences between that
eport of Molyneux et al. (18) and the present study. Our
tudy was much larger with more patients (1,191 vs. 236)
nd deaths (350 vs. 76). Indeed, there were twice as many
eaths in the lowest coenzyme Q10 tertile in our study as in
he whole cohort studied by Molyneux et al. (18). That
tudy stored plasma for up to 5.4 years before measurement
f coenzyme Q10. Concentration of coenzyme Q10 falls with
torage, and that may explain the lower levels of coenzyme
10 in the study of Molyneux et al. (12,18). Another
mportant difference was in the multivariable analyses per-
ormed. Molyneux et al. (18) adjusted for 5 baseline
ariables in addition to coenzyme Q10. We adjusted for 14
reviously identified independent predictors of outcome
21). Coenzyme Q10 may have been an independent pre-
ictor of death in the study of Molyneux et al. (18) only
ecause they did not fully adjust for differences in other
rognostic variables between patients with a lower or
igher coenzyme Q10 concentration. For example, when we
epeated the limited Cox proportional hazards analysis
escribed by Molyneux et al. (18) using median coenzyme
10 concentration, we found coenzyme Q10 to be an
ndependent predictor of mortality (p  0.048; data not
hown), although this was not the case after fuller adjust-
ent (Table 6). eWe also examined composites of fatal and nonfatal
vents, including that of death or hospital admission for
eart failure, in view of prior concerns that low coenzyme
10 might lead to worsening heart failure. As with mortal-
ty, coenzyme Q10 concentration was not an independent
redictor of any of these other outcomes.
As expected, treatment with rosuvastatin reduced serum
oenzyme Q10 concentration. In view of prior concerns that
tatin-induced reductions in coenzyme Q10 might be harm-
ul in heart failure, we examined the effect of rosuvastatin on
linical outcomes according to baseline serum coenzyme
10 concentration. Tertile analysis showed a numerically
igher event rate in statin-treated compared with placebo-
reated patients for all outcomes in patients with the lowest
oenzyme Q10 concentration. In the other 2 coenzyme Q10
ertiles, rosuvastatin treatment was associated with a numer-
cally lower event rate than placebo treatment. None of the
ests for interaction between baseline coenzyme Q10 con-
entration tertile and treatment was statistically significant,
lthough this is a test with low power and the p values were
orderline, ranging from 0.14 to 0.26.
Although we cannot completely exclude an adverse effect
f statin treatment in heart failure patients with a low
oenzyme Q10 concentration, we believe that several obser-
ations make such an effect unlikely. First, we could not
emonstrate that low coenzyme Q10 concentration, whether
spontaneous” or statin-induced, was independently associ-
ted with worse outcome in the multivariable analyses
escribed above. Second, close inspection of outcomes in
he lowest coenzyme Q10 tertile did not show any evidence
f increased risk of the “expected” clinical events, namely,
eath due to heart failure or heart failure hospitalization in
he rosuvastatin group compared with the placebo group. In
ddition, there was no worsening of NYHA functional class
n rosuvastatin-treated patients compared with placebo-
reated patients in the lowest coenzyme Q10 tertile. Indeed,
f there was an excess of any type of event, it was myocardial
nfarction and noncardiovascular death. Third, we did not
nd any evidence of the most predicted coenzyme Q10-
elated effect of statins, namely, muscle symptoms or in-
reased creatine kinase. Furthermore, there were no more
iscontinuations of rosuvastatin than placebo in the lowest
oenzyme Q10 tertile.
onclusions
lthough a low serum coenzyme Q10 concentration is
ssociated with worse outcomes in heart failure, that is
ecause it is a marker of more advanced disease and is not an
ndependent predictor of prognosis. Statin treatment re-
uced serum coenzyme Q10 concentration, but even in
atients with a low starting coenzyme Q10, statin therapy
as not associated with a significantly worse outcome,
lthough we had limited statistical power to completely
xclude this possibility. Although we cannot completely
xclude an interaction between coenzyme Q10 concentration
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arm was observed.
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